StockNews.AI
ASRT
StockNews.AI
167 days

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

1. Assertio will release Q4 and FY 2024 financial results on March 12. 2. The management will host an earnings call at 4:30 PM Eastern Time. 3. Investors can access the call via webcast or telephone for insights. 4. Assertio focuses on oncology, neurology, and pain management products. 5. The earnings call may provide critical insights into financial performance.

3m saved
Insight
Article

FAQ

Why Neutral?

Earnings reports can reflect prior performance trends but are uncertain until released. Past quarterly results have had mixed impacts on ASRT's stock price.

How important is it?

With earnings approaching, investor sentiment can shift based on performance expectations, making this relevant yet uncertain.

Why Short Term?

The March 12 earnings call will have immediate effects on stock perception and investor reactions, reflecting Q4 performance.

Related Companies

ACORXERSPFEAMGNJNJ
LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025, after the market close. Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time. To access the live webcast, conference call information, and other materials, please visit Assertio’s investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. For those wishing to join by telephone only, please dial +1-646-307-1963. The call ID is 3278948. A webcast replay of the call will be available approximately two hours after the call on Assertio’s investor website. About AssertioAssertio is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. Our focus is on supporting patients through marketing such products for oncology, neurology, and pain management. To learn more about Assertio, visit www.assertiotx.com. Investor Contact Matt KrepsDarrow Associates Investor Relations+1-214-597-8200mkreps@darrowir.com

Related News